Karuna Therapeutics Inc. (NASDAQ: KRTX) was downgraded by analysts at Leerink Partners, H.C. Wainwright and Maxim Group on Tuesday following ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change Downgrades Hot List Mergers and Acquisitions

Bristol-Myers Squibb (BMY) to buy RayzeBio (RYZB) for $4.1 billionDecember 26, 2023 7:56 AM Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBioDecember 26, 2023 7:13 AM Bristol Myers to buy RayzeBio for $4.1 billion in targeted cancer therapy pushDecember 26, 2023 7:08 AM RayzeBio (RYZB) to Resume Trading at 7:30 a.m. December 26, 2023 7:05 AM Bristol-Myers Squibb (BMY) Announces Acquisition of RayzeBio (RYZB) for $62.50 Per Share, $4.1 BillionDecember 26, 2023 7:00 AM  Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBioDecember 26, 2023 6:59 AM Form 8-K BRISTOL MYERS SQUIBB CO For: Dec 22December 22, 2023 4:16 PM Midday movers: Nike, Karuna Therapeutics and moreDecember 22, 2023 11:33 AM PureTech Founded Entity Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 BillionDecember 22, 2023 9:13 AM Bristol-Myers Squibb (BMY) option IV into acquiring Karuna Therapeutics (KRTX) December 22, 2023 7:19 AM Bristol Myers to buy schizophrenia drugmaker Karuna Therapeutics for $14 billionDecember 22, 2023 7:00 AM Stifel highilghts these 2 stocks on news Bristol Myers will acqurie KarunaDecember 22, 2023 7:00 AM Bristol-Myers Squibb (BMY) to Acquire Karuna Therapeutics (KRTX) for $330/sh or $14BDecember 22, 2023 6:59 AM Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna TherapeuticsDecember 22, 2023 6:59 AM